Solid Biosciences Inc., which acquired UF startup AavantiBio, announced a non-exclusive worldwide license and collaboration agreement with Kinea Bio for the use of Solid’s proprietary, next-generation capsid, AAV-SLB101, for the development and commercialization of KNA-155, an investigational dual AAV gene therapy targeting dysferlinopathy, a form of limb-girdle muscular dystrophy type 2B/R2 (LGMD2B/R2).
Under the terms of the agreement, Solid granted Kinea Bio a non-exclusive worldwide license to utilize AAV-SLB101 as the delivery backbone for KNA-155, which is advancing into IND-enabling preclinical activities. In return, Solid receives an upfront fee and is eligible for additional payments upon the achievement of certain development and sales milestones and tiered royalties on net sales.
Read more about Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101.
